Progress: Procedure completed
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | CONT | CZARNECKI Ryszard ( ECR) | MARINESCU Marian-Jean ( EPP), CREȚU Corina ( S&D), WIEZIK Michal ( Renew), RIVASI Michèle ( Verts/ALE), KUHS Joachim ( ID), OMARJEE Younous ( GUE/NGL) |
Committee Opinion | ENVI | ||
Committee Opinion | ITRE |
Lead committee dossier:
Subjects
Events
The European Parliament decided to grant discharge to the Executive Director of the Innovative Medicines Initiative 2 Joint Undertaking (now the Innovative Health Initiative Joint Undertaking) in respect of the implementation of its budget for the financial year 2020 and approve the closure of the Joint Undertaking’s accounts.
Noting that the Court of Auditors found that the annual accounts of the Joint Undertaking for the financial year 2020 present fairly the financial situation of the Joint Undertaking on 31 December 2020, as well as the results of its operations, Parliament adopted, by 572 votes to 37 with 37 abstentions, a resolution containing a series of observations which form an integral part of the discharge decision.
Budgetary and financial management
The final IMI2 Joint Undertaking available budget for 2020, including re-entered unused appropriations of previous years, assigned revenues, and reallocations to the next year, was EUR 276 538 561 in commitment appropriations (of which EUR 269 829 327 from the Union budget) and EUR 241 559 114 in payment appropriations (of which EUR 232 349 880 from the Union budget). The budget execution of the commitment appropriations and the payment appropriations reached 98.66 % and 97.08 %, respectively.
Members noted that out of the EUR 1 billion of contributions to be made by private members to operational activities of the IMI Joint Undertaking, by the end of 2020 the IMI Joint Undertaking had reported and validated in-kind and cash contributions of EUR 759 471 000 from private members, of which EUR 737 573 000 in-kind and EUR 21 898 000 in cash contributions. During 2020, 11 projects were running under the IMI Joint Undertaking, of which 3 had ended by 31 December 2020.
The IMI Joint Undertaking utilisation rate for payment appropriations for the Seventh Framework Programme projects was 96 %.
The Joint Undertaking concluded 19 new signed grant agreements, including 8 projects for the emergency call for proposals on coronavirus treatments and diagnostics.
Once again, Parliament called for a harmonisation of the calculation of in-kind contributions to the Joint Undertaking.
Other observations
The resolution also contains a series of observations on performance, staff and internal controls.
In particular, it noted the following:
- the IMI2 Joint Undertaking launched a fast-track call for proposals on coronavirus treatments and diagnostics, resulting in 8 projects. The Undertaking also launched three additional calls for proposals relating to topics such as rare diseases, infectious diseases, cancer, neurodegenerative diseases and autoimmune diseases;
- 19 new grant agreements for projects were signed with a total combined budget of over EUR 380 million, bringing the total IMI2 Joint Undertaking’s portfolio to 167 projects;
- an important contribution to the common European response to the COVID-19 pandemic was made by the Undertaking and it reallocated EUR 45 million of its 2020 budget to a fast-track call for proposals launched in March 2020;
- the issue of intellectual property rights needs to be addressed in all contracts;
- on 31 December 2020, 53 of the 56 positions in the staff establishment plan of the IMI2 Joint Undertaking were occupied, five positions were filled during 2020, three for temporary agents and two for contract agents;
- IMI2 set up reliable ex-ante control procedures for financial and operational desk reviews;
- systemic errors were found in the personnel costs declared by beneficiaries, in particular on the part of SMEs and new beneficiaries. Therefore, Parliament called on the Joint Undertaking should strengthen its internal control systems, given that SMEs and new beneficiaries are more error-prone.
Documents
- Debate in Parliament: Debate in Parliament
- Decision by Parliament: T9-0190/2022
- Committee report tabled for plenary, single reading: A9-0072/2022
- Committee report tabled for plenary: A9-0072/2022
- Supplementary non-legislative basic document: 06005/2022
- Amendments tabled in committee: PE703.130
- Committee draft report: PE698.997
- Court of Auditors: opinion, report: OJ C 458 12.11.2021, p. 0020
- Court of Auditors: opinion, report: N9-0045/2022
- Non-legislative basic document: COM(2021)0381
- Non-legislative basic document: EUR-Lex
- Non-legislative basic document published: COM(2021)0381
- Non-legislative basic document published: EUR-Lex
- Non-legislative basic document: COM(2021)0381 EUR-Lex
- Court of Auditors: opinion, report: OJ C 458 12.11.2021, p. 0020 N9-0045/2022
- Committee draft report: PE698.997
- Amendments tabled in committee: PE703.130
- Supplementary non-legislative basic document: 06005/2022
- Committee report tabled for plenary, single reading: A9-0072/2022
Votes
Décharge 2020: entreprise commune «Initiative en matière de médicaments innovants 2» - Discharge 2020: Innovative Medicines Initiative 2 Joint Undertaking - Entlastung 2020: Gemeinsames Unternehmen „Initiative Innovative Arzneimittel 2“ - A9-0072/2022 - Ryszard Czarnecki - Proposition de résolution (ensemble du texte) #
Amendments | Dossier |
13 |
2021/2154(DEC)
2022/02/03
CONT
13 amendments...
Amendment 1 #
Proposal for a decision 1 Paragraph 1 1. Grants the Executive Director of the Innovative Health Initiative Joint Undertaking discharge in respect of the implementation of the Joint Undertaking’s budget for the financial year
Amendment 10 #
Motion for a resolution Paragraph 13 a (new) 13 a. Notes that the issue of intellectual property rights needs to be addressed in all contracts which may produce an intended outcome of the performance, or result, such as studies, analysis, or evaluations; notes that it aims at safeguarding the rights of individual creators but also provide details how the rights will be used in the future; notes that since the purchases are done with public money, the results should be transparent and accessible to the public; calls the IMI2 Joint Undertaking for a clarification of the intellectual property rights and more transparency when it comes to the result of the research;
Amendment 11 #
Motion for a resolution Paragraph 15 a (new) 15 a. Notes that the annual activity report 2020 highlighted that for the evaluation experts, IMI2 Joint Undertaking used 235 experts from 29 countries. Among this population of experts, 105 were female and 130 male; welcomes that the IMI2 Joint Undertaking continues to improve gender balance in this respect;
Amendment 12 #
16. Notes that during the lockdown period, the IMI2 Joint Undertaking staff switched to full time teleworking, with staff able to access all the files, tools and resources they needed from day one, the switch to working from home was also facilitated by the fact that the IMI2 Joint Undertaking had adopted a number of the Commission’s standard tools, such as ARES, SYSPER and the full set of Horizon 2020 programme management IT tools; notes, moreover, that the IMI2 Joint Undertaking and the other joint undertakings who work in the same building agreed on a single set of rules for staff who exceptionally have to work at the office, to ensure staff safety and wellbeing, and also outlined a phased return to the office; notes with concern the challenges associated with the COVID-19 pandemic for staff, especially taking into account different living situations, lack of access to office space and possible effects of isolation; asks the IMI2 Joint Undertaking to focus on staff wellbeing, stress management and work and life balance; asks management to ensure there is appropriate support structures in place to ensure the psychological well- being of staff;
Amendment 13 #
Motion for a resolution Paragraph 21 a (new) 21 a. Emphasises that the Court’s finding confirmed persistent systemic errors for declared personnel costs and that in particular, small and medium- sized enterprises (SMEs)and new beneficiaries are more error-prone than other beneficiaries. Highlights that those errors are also regularly reported by the ex post audits of the Common Audit Service and its contracted auditors; emphasises therefore that streamlining of the Horizon 2020 rules for the declaration of personnel costs and wider use of simplified cost options is a precondition to stabilise error rates to below materiality level. IMI2 Joint Undertaking is also encouraged to strengthen its internal control systems to address the increased risk regarding SMEs and new beneficiaries;
Amendment 2 #
Motion for a resolution Paragraph 5 5. Notes that out of the EUR 1 425 000 000 of in-kind and cash contributions to be made by industry members to the operational activities of the IMI2 Joint Undertaking, in-kind contributions of EUR 317 206 000 and cash contributions of EUR 20 717 000 were reported and validated, and that additionally, EUR 7 064 000 in cash and EUR 34 972 000 of in-kind contributions by associated members were reported and validated; notes that, consequently, at the end of 2020, the total contributions of industry members and associated partners to the Horizon 2020 activities of the IMI2 Joint Undertaking amounted to 379 959 000, compared to the
Amendment 3 #
Motion for a resolution Paragraph 5 a (new) 5 a. Notes that there are different procedures across the Joint Undertakings regarding the calculation for the in-kind contributions and calls for a harmonisation of the in-kind contribution calculation across the Joint Undertakings;
Amendment 4 #
Motion for a resolution Paragraph 6 6. Notes from the Court’s report that the IMI2 Joint Undertaking experiences long project durations due to the nature of its research and that this situation is an example of varying degrees of achievement of contribution targets set by the Joint Undertakings’ regulations in relation to Horizon 2020 activities, and that this presents the risk that the level of administrative resources needed to manage the Joint Undertaking’s funds in a timely manner, may not be sufficient, due to an increasing number of projects from multiple Multiannual Financial Framework programmes being implemented simultaneously; calls on the IMI2 Joint Undertaking for more transparency in the decision making process for its research priorities and for communicating the chosen method in their next annual report;
Amendment 5 #
Motion for a resolution Paragraph 6 6. Notes from the Court’s report that the IMI2 Joint Undertaking experiences long project durations due to the nature of its research and that this situation is an example of varying degrees of achievement of contribution targets set by the Joint Undertakings’ regulations in relation to Horizon 2020 activities, and that this
Amendment 6 #
Motion for a resolution Paragraph 8 8. Notes from the Court’s report that the IMI2 Joint Undertaking’s practice of reactivating unused payment appropriations from previous years to the extent of open administrative commitments, results in an accumulation of unused payment appropriations and that, aggravated by the impact of the COVID-19 pandemic, it resulted in a low budget implementation rate for the IMI2 Joint Undertaking’s Title 2 administrative budget of 51
Amendment 7 #
Motion for a resolution Paragraph 8 8. Notes from the Court’s report that the IMI2 Joint Undertaking’s practice of reactivating unused payment appropriations from previous years to the extent of open administrative commitments, results in an accumulation of unused payment appropriations and that, aggravated by the impact of the COVID-19 pandemic, it resulted in a low budget implementation rate for the IMI2 Joint Undertaking’s administrative budget of 51
Amendment 8 #
Motion for a resolution Paragraph 9 9. Notes that the IMI2 Joint Undertaking launched a fast-track call for proposals on coronavirus treatments and diagnostics, resulting in 8 projects; notes, moreover, the launch of three additional calls for proposals featuring topics on rare diseases, infectious diseases, cancer, neurodegenerative diseases and autoimmune diseases; notes, furthermore, the signing of 19 new grant agreements for projects with a total combined budget of over EUR 380 000 000, bringing the total IMI2 Joint Undertaking’s portfolio to 167 projects; notes that the new projects focus on cancer, diabetes, obesity, digital health, artificial intelligence, advanced therapies, drug discovery, and environmental issues; recalls that by selecting commercially interesting research topics for the pharmaceutical industry (such as diabetes or obesity) the IMI2 Joint Undertaking is not meeting the goals that justified its creation, namely improving the development and availability of health technologies for unmet medical needs; thus, considers that the interim evaluation of IMI2 Joint Undertaking realised in 2017 by the Commission and concluding that the added value of IMI2 Joint Undertaking for patients and for society in general is difficult to demonstrate is still valid;
Amendment 9 #
Motion for a resolution Paragraph 11 11. Notes that several new tools and processes generated by IMI2 Joint Undertaking projects have been implemented by the industry participants (examples of such implementation are animal models, standards, biomarkers, standard operating procedures, use of screening platforms, clinical trial networks, etc.). Data also shows that there were 176 implementation results in IMI2 Joint Undertaking (versus a target of 50) and 482 implementation results for the IMI Joint Undertaking and IMI2 Joint Undertaking programmes considered together; notes, in addition, that 60
source: 703.130
|
History
(these mark the time of scraping, not the official date of the change)
events/4/docs |
|
events/6 |
|
procedure/final |
|
procedure/stage_reached |
Old
Procedure completed, awaiting publication in Official JournalNew
Procedure completed |
docs/1 |
|
events/5/docs/0/url |
https://www.europarl.europa.eu/doceo/document/TA-9-2022-0190_EN.html
|
docs/5 |
|
events/5/summary |
|
procedure/subject/8.70.03.10 |
2020 discharge
|
docs/0 |
|
docs/0 |
|
docs/4 |
|
docs/5 |
|
events/0 |
|
events/0 |
|
events/3/docs |
|
events/4 |
|
events/5 |
|
forecasts |
|
procedure/stage_reached |
Old
Awaiting Parliament's voteNew
Procedure completed, awaiting publication in Official Journal |
procedure/subject/8.70.03.10 |
2020 discharge
|
forecasts |
|
forecasts |
|
events/3 |
|
procedure/stage_reached |
Old
Awaiting committee decisionNew
Awaiting Parliament's vote |
docs/3 |
|
events/2 |
|
docs/2/docs/0/url |
https://www.europarl.europa.eu/doceo/document/CONT-AM-703130_EN.html
|
docs/2 |
|
forecasts |
|
docs/1/docs/0/url |
https://www.europarl.europa.eu/doceo/document/CONT-PR-698997_EN.html
|
docs/1 |
|
committees/0 |
|
committees/0 |
|
committees/1/opinion |
False
|
events/1 |
|
procedure/dossier_of_the_committee |
|
procedure/stage_reached |
Old
Preparatory phase in ParliamentNew
Awaiting committee decision |
commission |
|
committees/0 |
|
committees/0 |
|
committees/2/opinion |
False
|